Treatment of Hyperphosphatemia in CKD Stage 5 on Dialysis When Initial Phosphate Binder Therapy Has Not Reached Target
Clinical Scenario
This protocol addresses adults with chronic kidney disease (CKD) stage 5 who are on dialysis and whose serum phosphorus has not been controlled by initial phosphate binder treatment — in the absence of hypercalcemia.
Why This Protocol Applies
Previous treatment insufficientMonotherapy with a calcium-based or non-calcium-based phosphate binder — including calcium carbonate, calcium acetate, sevelamer, lanthanum carbonate, sucroferric oxyhydroxide, or ferric citrate — did not achieve the target serum phosphorus of 3.5 to 5.5 mg/dL.
This protocol represents the structured next step for that clinical situation.
Next-Step Approach (Partial Overview)
The next line of management involves a combination of phosphate binder approaches. Which agents are combined and under what specific conditions is defined in the full protocol.
Clinical goal:
Serum phosphorus 3.5 – 5.5 mg/dL
References
Stage 5 patients may use either calcium or non-calcium-based binders, and if a dialysis patient remains hyperphosphatemic (>5.5 mg/dL) it is reasonable to use a combination of both.
In CKD stage 5, hypercalcemia can increase the risk of cardiovascular disease.
The target phosphorus concentration for dialysis patients is 3.5 to 5.5 mg/dL.
View source ↗